Bivalent biogenic amine reuptake inhibitors

Bioorganic & Medicinal Chemistry Letters
2003.0

Abstract

A series of aryltropane-based bivalent ligands was prepared and investigated for binding potency and for their ability to inhibit reuptake of human dopamine, serotonin and norepinephrine transporters. The bivalent ligand 4, comprised of linking an aryltropane by an octamethylene spacer showed high efficacy for the human dopamine transporter and had a discrimination ratio of 130.

Knowledge Graph

Similar Paper

Bivalent biogenic amine reuptake inhibitors
Bioorganic & Medicinal Chemistry Letters 2003.0
Pharmacological and Behavioral Analysis of the Effects of Some Bivalent Ligand-Based Monoamine Reuptake Inhibitors
Journal of Medicinal Chemistry 2001.0
Biaryl Analogues of Conformationally Constrained Tricyclic Tropanes as Potent and Selective Norepinephrine Reuptake Inhibitors:  Synthesis and Evaluation of Their Uptake Inhibition at Monoamine Transporter Sites
Journal of Medicinal Chemistry 2003.0
1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors
Bioorganic & Medicinal Chemistry Letters 2009.0
Discovery of novel conformationally constrained tropane-based biaryl and arylacetylene ligands as potent and selective norepinephrine transporter inhibitors and potential antidepressants
Bioorganic & Medicinal Chemistry Letters 2005.0
Synthesis and transporter binding properties of (R)-2β,3β- and (R)-2α,3α-diaryltropanes
Bioorganic & Medicinal Chemistry Letters 1998.0
Structure−Activity Relationship Comparison of (S)-2β-Substituted 3α-(Bis[4-fluorophenyl]methoxy)tropanes and (R)-2β-Substituted 3β-(3,4-Dichlorophenyl)tropanes at the Dopamine Transporter
Journal of Medicinal Chemistry 2003.0
Synthesis and Monoamine Transporter Binding Properties of 2,3-Diaryltropanes
Journal of Medicinal Chemistry 2005.0
Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes
Bioorganic & Medicinal Chemistry Letters 2005.0
Design and Synthesis of 4-Heteroaryl 1,2,3,4-Tetrahydroisoquinolines as Triple Reuptake Inhibitors
ACS Medicinal Chemistry Letters 2014.0